BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 24613722)

  • 1. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH; Kang NH; Niles LP
    Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH; Kang NH; Niles LP
    Brain Res; 2016 Feb; 1633():115-125. PubMed ID: 26740407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral upregulation of α-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment.
    Carriere CH; Kang NH; Niles LP
    Exp Toxicol Pathol; 2017 Feb; 69(2):109-114. PubMed ID: 27986376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein.
    Monti B; Gatta V; Piretti F; Raffaelli SS; Virgili M; Contestabile A
    Neurotox Res; 2010 Feb; 17(2):130-41. PubMed ID: 19626387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of L-thyroxin in counteracting rotenone induced neurotoxicity in rats.
    Salama M; Helmy B; El-Gamal M; Reda A; Ellaithy A; Tantawy D; Mohamed M; El-Gamal A; Sheashaa H; Sobh M
    Environ Toxicol Pharmacol; 2013 Mar; 35(2):270-7. PubMed ID: 23357603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotine-Induced Neuroprotection in Rotenone In Vivo and In Vitro Models of Parkinson's Disease: Evidences for the Involvement of the Labile Iron Pool Level as the Underlying Mechanism.
    Mouhape C; Costa G; Ferreira M; Abin-Carriquiry JA; Dajas F; Prunell G
    Neurotox Res; 2019 Jan; 35(1):71-82. PubMed ID: 30006684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease.
    Khurana N; Gajbhiye A
    Neurotoxicology; 2013 Dec; 39():57-64. PubMed ID: 23994302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
    Saravanan KS; Sindhu KM; Mohanakumar KP
    Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
    Xue YQ; Zhao LR; Guo WP; Duan WM
    Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
    Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
    Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
    Sharma R; McMillan CR; Tenn CC; Niles LP
    Brain Res; 2006 Jan; 1068(1):230-6. PubMed ID: 16375867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
    Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease.
    Thomas Tayra J; Kameda M; Yasuhara T; Agari T; Kadota T; Wang F; Kikuchi Y; Liang H; Shinko A; Wakamori T; Vcelar B; Weik R; Date I
    Brain Res; 2013 Mar; 1502():55-70. PubMed ID: 23380533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease.
    Sharma R; McMillan CR; Niles LP
    J Pineal Res; 2007 Oct; 43(3):245-54. PubMed ID: 17803521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
    Decressac M; Pain S; Chabeauti PY; Frangeul L; Thiriet N; Herzog H; Vergote J; Chalon S; Jaber M; Gaillard A
    Neurobiol Aging; 2012 Sep; 33(9):2125-37. PubMed ID: 21816512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
    Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
    Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.